Treatment of hypopituitarism with recombinant somatropin for 1 year.
Twenty-five hypopituitary patients were treated with recombinant somatropin for 1 year at a dosage of 0.5 IU/kg/week. In previously untreated patients (n = 16), heights increased by between 4.5 and 10.2 cm, with a mean height velocity of 7.7 +/- 1.8 cm/year (mean +/- SD). In previously treated patients (n = 9), heights increased by between 3.9 and 7.6 cm, with a mean height velocity of 5.8 +/- 1.0 cm/year, similar to that observed during previous treatment with pituitary GH. Anti-GH antibodies were observed in two patients at a low titre. The antibodies disappeared in one patient during the treatment. These data indicate that recombinant somatropin has a growth promoting effect and low immunogenicity.
Takano
K
K
Committee for Treatment of Pituitary Dwarfism, Foundation for Growth Science in Japan.
Shizume
K
K
Hibi
I
I
Okuno
A
A
Hanyu
K
K
Suwa
S
S
Nakajima
H
H
Kondo
T
T
Kato
K
K
Iwatani
N
N
D000293:Adolescent; D000365:Age Determination by Skeleton; D000917:Antibody Formation; D001827:Body Height / Q000187:drug effects; D002648:Child; D005260:Female; D013006:Growth Hormone / Q000172:deficiency / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007018:Hypopituitarism / Q000188:drug therapy*; D008297:Male; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D013006:Growth Hormone